We examined 100 patients with non-small cell lung cancer (NSCLC). In addition to surgery there was performed neoadjuvant chemotherapy (2-3 cycles) EP (cisplatin at a dose of 80 mg/m2 on first day + etoposide at a dose of 120 mg/ m2 on days 1,3,5). There were studied the levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) as prognostic factors in the use of neoadjuvant chemotherapy in patients with NSCLC. The control group consisted of 30 healthy volunteers. The baseline level of bFGF was necessary for the prediction of combined treatment in patients with NSCLC stage III. The threshold value bFGF>10,2 ng/ml allowed predicting a good effect from chemotherapy with a sensitivity of 71,4% and specificity of 80,6%, while the sensitivity of VEGF in terms of forecasting bicycles reached 42,9 %. The resulting algorithm for predicting of the effect of neoadjuvant chemotherapy of patients with NSCLC provided perspectives to improve the outcomes of such patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: An American Multicenter Analysis.
Ann Surg Oncol
January 2025
Department of Surgery, NorthShore University Health System, Evanston, IL, USA.
Background: As the population ages, the number of octogenarians with pancreatic ductal adenocarcinoma (PDAC) continues to rise. Morbidity and mortality following pancreatectomy have improved owing to safer surgery and better chemoradiation regimens. This study compares the outcomes and multimodality utilization in octogenarians (≥80 years) who underwent pancreaticoduodenectomy (PD) for PDAC, with a younger cohort.
View Article and Find Full Text PDFConduction system metastasis in a patient with carcinoma oesophagus.
BMJ Case Rep
January 2025
Cardiology, AIIMS, New Delhi, India
A young man in his 30s presented to us with multiple episodes of syncope and exertional dyspnoea for the last 2 weeks. He was diagnosed with squamous cell carcinoma of the lower one-third of the oesophagus in 2021 for which he was treated with neoadjuvant chemoradiotherapy, followed by McKeown oesophagectomy. At 2-year follow-up, he had developed a soft tissue swelling in the scalp, which was diagnosed as a tumour recurrence and radiotherapy was initiated.
View Article and Find Full Text PDFNeoadjuvant chemotherapy in locally advanced colon cancer: A systematic review with proportional meta-analysis.
Eur J Surg Oncol
December 2024
Department of Medical Oncology, Catharina Hospital, Eindhoven, Netherlands.
Neoadjuvant chemotherapy is suggested in locally advanced colon cancer. Data on improved long-term oncological outcomes are lacking, which hampers the implementation in clinical practice. This systematic review provides an overview of the benefits and drawbacks of neoadjuvant chemotherapy in patients with locally advanced colon cancer.
View Article and Find Full Text PDFChronic stress-induced cholesterol metabolism abnormalities promote ESCC tumorigenesis and predict neoadjuvant therapy response.
Proc Natl Acad Sci U S A
February 2025
Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450000, China.
Recent studies have demonstrated that chronic stress can enhance the development of multiple human diseases, including cancer. However, the role of chronic stress in esophageal carcinogenesis and its underlying molecular mechanisms remain unclear. This study uncovered that dysregulated cholesterol metabolism significantly promotes esophageal carcinogenesis under chronic stress conditions.
View Article and Find Full Text PDFNeoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint?
Curr Opin Oncol
December 2024
Université Libre de Bruxelles, Hôpital Universitaire de Bruxelles, Instiut Jules Bordet, Departement of Medical Oncology.
Purpose Of Review: This review evaluates by analyzing recent studies whether pathological complete response (pCR) can be used as a reliable surrogate marker for overall survival (OS) in melanoma treated with neoadjuvant immunotherapy.
Recent Findings: Trials like Neo-Combi, Neo-Trio and COMBI-Neo show that pCR is crucial for long-term success in targeted therapy for melanoma, while studies like OpACIN-neo and SWOG S1801 demonstrate that immunotherapy can provide durable benefits even with partial responses. Findings from NADINA and the INMC analysis highlight that immunotherapy achieves higher pathologic response rates and improved survival outcomes, offering broader benefits compared to the pCR-dependent outcomes of targeted therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!